Cover
Vol. 2 No. 2 (2024)

Published: August 31, 2024

Pages: 69-81

Original Article

Psoriasis drug use survey

Enas Maytham Dayem 1 Dhuha Ali Haseeb Aya Baset Ali Ali Mohammed Fleih Fatima Kareem Ali Mohammed Fareed Hameed 2
1Students of Pharmacy College, Al-Nahrain University, Baghdad, Iraq
2Department of Pharmacology and Toxicology, College of pharmacy, Al-Nahrain University, Baghdad, Iraq
History
  • Received: June 30, 2024
  • Available Online: August 31, 2024

Abstract

Psoriasis is a chronic immuno-mediated inflammatory disease of 2.3% prevalence in Iraqi the etiology of the disease is not identified well. A wide variation in disease picture and response to treatment occur due to the complexity of the disease. The study includes 75 male and female people diagnosed with psoriasis. General data and treatment used have been analyzed. A questionnaire is prepared. The study shows that there were twenty-one patients aged between 15 and 24 years, thirty-three patients aged between 25 and 34 years, eight patients aged between 35 and 44 years, and thirteen patients were identified as being older than 44 years. The study shows that the distribution of patients is such that fifty-five percent are male, while forty-five percent are female. Betamethasone was most steroid used. Most of the patients repeat the treatment courses more than two times and most of the patients participated in the study use only one drug. In Conclusion both topical and systemic treatment is used and mostly steroids were the common used group.

Keywords

References

  1. Alsamarai AGM. Prevalence of skin diseases in Iraq. Int J Derm. 2009;48(7):734–9.
  2. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–9.
  3. Gudjonsson JE, Elder JT. Psoriasis. In: Goldsmith A, Katz SI, Gilcrest BA, Paller AS, et al., editors. Dermatology in General Medicine. 8th ed. New York: McGraw-Hill; 2012. pp. 197–231.
  4. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One. 2012;7(12):e52935. doi: 10.1371/journal.pone.0052935.
  5. Sterry W, Paus R, Burgdorf W. Dermatology (Thieme Clinical Companions). ISBN 1-58890-258-7.
  6. Rajguru JP, Maya D, Kumar D, Suri P, Bhardwaj S, Patel ND. Update on psoriasis: a review. Journal of Family Medicine and Primary Care. 2020;9(1):20.
  7. Thiers BH. The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis. J Am Acad Dermatol. 1997;37(3 pt 2):S69–71.
  8. Whalen K, editor. Lippincott Illustrated Reviews: Pharmacology. 7th ed.
  9. Dinulos JH, editor. Habif’s Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 7th ed. 2021.
  10. National Psoriasis Foundation. www.psoriasis.org. Accessed June 29, 2015.
  11. DiPiro CV, Schwinghammer T, editors. Pharmacotherapy Handbook. 11th ed. 2021.
  12. Wu T, Duan X, Chen S, Chen X, Yu R, Yu X. Association between psoriasis and erectile dysfunction: A meta-analysis. J Sex Med. 2018;15(6):839–47.
  13. Al Idrisi HA, Alhamdi K, Mansour AA. Is there any association between psoriasis and hashimoto’s thyroiditis? Cureus. 2019;11(3):115.
  14. Aldeen A, Murad K, Mohammed W, Fibms H. Incidence of psoriasis in patients with different skin in Baquba city. 2017;12(1):25–28.
  15. Al-Imam AM. A case of remitting psoriasis in association with hyperthyroidism in a morbidly obese Iraqi female. 2017;2(1):1–4.
  16. Khadhim MM, Ali AI. Associations of specific HLA-C loci and sociodemographic factors with the prevalence of type I psoriasis in Iraqi patients. Nano Biomed Eng. 2018;10(4):328–33.
  17. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–85.
  18. Sinniah B, Saraswathy DS, Prashant BS. Epidemiology of psoriasis in Malaysia: a hospital based study. Med J Malaysia. 2010;65:112–114.
  19. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated Comorbidity (IMPACT) Project Team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–385.
  20. Egeberg A, Skov L, Gislason GH, Thyssen JP, Mallbris L. Incidence and prevalence of psoriasis in Denmark. Acta Derm Venereol. 2017;97:808–812.
  21. Plunkett A, Merlin K, Gill D, Zuo Y, Jolley D, Marks R. The frequency of common nonmalignant skin conditions in adults in central Victoria, Australia. Int J Dermatol. 1999;38:901–908.
  22. Valenzuela F, Silva P, Valdes MP, Papp K. Epidemiology and quality of life of patients with psoriasis in Chile. Actas Dermosifiliogr. 2011;102:810–816.
  23. Griffiths CE, Camp RD, Baker JN. Psoriasis. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s Textbook of Dermatology Volume 2. 7th ed. Oxford (UK): Blackwell Publishing; 2004. p. 35.1–35.2.
  24. Cakmur H, Derviş E. The relationship between quality of life and the severity of psoriasis in Turkey. Eur J Dermatology. 2015;25(2):169–76.